Alzheimer’s & Dementia Care

Mainstream outlets reported that on May 12, 2026 the FDA expanded approval of Auvelity for agitation associated with Alzheimer’s dementia in adults, marking it as the first non‑antipsychotic option for that indication based on two randomized trials (a five‑week efficacy study and a relapse‑prevention trial). Coverage noted the agency’s safety warnings — dizziness, GI upset, seizures, elevated blood pressure, possible mania in susceptible patients, and increased suicidal thoughts in younger adults — and framed the approval as a new prescribing option that will require close monitoring as use widens.

Missing from mainstream reports were many trial and policy details that would change interpretation: sample sizes, absolute effect sizes/NNT, patient characteristics (dementia stage, concomitant meds), duration of follow‑up, subgroup safety signals, and any comparison with antipsychotics or nonpharmacologic management. Opinion pieces filled some gaps by pressing broader themes — calls to incentivize drug repurposing, warnings about approving medications on short trials, and views that new FDA leadership may accelerate approvals — but independent context was still lacking on cost/coverage, conflicts of interest, post‑marketing surveillance plans (e.g., REMS), and baseline epidemiology. Helpful missing facts for readers would include concrete efficacy and adverse‑event rates, long‑term outcomes, comparative effectiveness versus current standards, and historical data on harms from antipsychotics in dementia; social media offered no additional insights in this sample, while contrarian voices emphasized that “less invasive” does not automatically mean safer and that repurposing still requires rigorous long‑term evidence.